1005 results about "Primary treatment" patented technology

A method of disposing waste includes the step of forming a primary waste pond called an Advanced Facultative Pond (AFP). A stable microbiological methane fermentation zone is established within the AFP. The system constitutes a complete primary treatment of organic waste and wastewater that does not require daily sludge handling typically associated with organic waste treatment and disposal. The method of the invention converts organic compounds, including settleable solids, into methane. The invention controls sulfide odors from methane fermentation. The invention also provides a method of filtering raw wastewater through a bed of fermenting organic solids suspended by gas evolved in a fermentation zone. Hydrogen sulfide is oxidized in accordance with the invention. The technique of the invention biologically increases pH near the pond surface, thus retaining hydrogen sulfide in solution in the pond water. The biological increasing of the pH level near the pond surface increases the rate of die-away of pathogenic bacteria. The invention transforms proteins and other organic nitrogen compounds to nitrogen gas. The invention also transforms proteins and other organic nitrogen compounds to nitrogen gas; the invention detoxifies chlorinated hydrocarbons and volatile organic compounds; the invention captures and stores gases evolved from methane fermentation; the invention removes heavy metals, while establishing meromixis in fermentation cells or zones within primary wastewater ponds.

A process for the production of highly purified water 44 from Fischer-Tropsch reaction water 12 includes distillation 14 as a primary treatment stage, biological treatment including anaerobic digestion 20 and aerobic digestion 22 as a secondary treatment stage, solid-liquid separation 32 as a tertiary treatment stage and a dissolved salt and organic removal stage 40 as final treatment stage.

Systems and methods affect tightening of the pyloric sphincter and / or serve to mediate or moderate receptive relaxation of muscles in the stomach, to treat or mitigate various physiologic conditions, such as obesity, biliary reflex, GERD, and / or Barrett's esophagus. The systems and methods may be used as either a primary treatment modality, or applied as a supplementary treatment before, during or after a primary intervention.

A process for the production of purified water from Fischer-Tropsch reaction water wherein the purified water is an aqueous stream having a COD of between 20 and 500 mg / l, a pH of between 6.0 and 9.0, a suspended solids content of less than 250 mg / l and a total dissolved solids content of less than 600 mg / l, and wherein the process includes at least the steps of a primary treatment stage comprising an equilibrium staged separation process having at least one stage for removing at least a fraction of non-acid oxygenated hydrocarbons from the Fischer-Tropsch reaction water to produce a primary water enriched stream, a secondary treatment stage comprising liquid-liquid extraction for removing at least a fraction of organic acids from at least a portion of the primary water enriched stream to produce a secondary water enriched stream, a tertiary treatment stage comprising biological treatment for removing at least a fraction of acidic oxygenated hydrocarbons from at least a portion of the secondary water enriched stream to produce a tertiary water enriched stream and a quartic treatment stage comprising solid-liquid separation for removing at least some solids from at least a portion of the tertiary water enriched stream.

Systems and methods that treat disorders of the gastrointestinal tract by applying one or more treatment agents to tissue at or near the region where abnormal neurological symptoms or abnormal tissue conditions exist. The treatment agent is selected to either disrupt the abnormal nerve pathways and / or to alleviate the abnormal tissue conditions. The treatment agent can include at least one cytokine and / or at least one vanilloid compound to evoke a desired tissue response. The systems and methods can be used a primary treatment modality, or as a neoadjuvent or adjuvant treatment modality.

The present invention describes a novel treatment for movement disorders, including tardive dyskinesia, tic disorders, Tourette's syndrome, and blepharospasm, and other focal dystonias. The treatment of the present invention utilizes agents that simultaneously act as NMDA-type glutamate receptor antagonists and GABA-A receptor agonists. Preferably these two activities are characteristic of a single agent, for example acamprosate. Alternatively, separate agents having these activities can be combined and administered together. The invention also provides a third agent that acts as a non-competitive NMDA-receptor blocking agent or ion channel blocker that augments the effect of the primary treatment. A particularly preferred ion channel blocking agent is magnesium. Alternatively, magnesium can be administered alone for prevention and treatment of movement disorders.

Systems and methods to treat wastewater are described herein. A wastewater treatment system may include a primary treatment system, a secondary treatment system, a disinfection treatment system, a solids treatment system, one or more fluid treatment systems, or combinations thereof.